NPACT- Naturally occuring Plant based Anticancerous Compound-Activity-Target DataBase

Compound: Ursolic acid

TargetsGene NameGene IDCancerCell LinesIC50ED50EC50GI50RemarkReferences
BAK1BCL2-antagonist/killer 1578HepatomaHep G2----Results suggested that the level of Bak protein was enhanced in a dose-dependent manner induced by UA treatment in R-HepG2 cells20630652
CASP3caspase 3, apoptosis-related cysteine peptidase836Hepatocellular CarcinomaH22----Inhibition rate of 52.8% was observed in tumor growth in Ursolic acid treated xenografts. The result of western blot showed that the protein level of Caspase-3 was elevated after treatment with UA21716649
CASP8caspase 8, apoptosis-related cysteine peptidase841Hepatocellular CarcinomaH22----Inhibition rate of 52.8% was observed in tumor growth in Ursolic acid treated xenografts. The result of western blot showed that the protein level of Caspase-8 was elevated after treatment with UA21716649
PTPN1protein tyrosine phosphatase, non-receptor type 15770Breast adenocarcinomaMCF-73.6±0.2 µM---PTP1B is overexpressed in human breast cancer, and inhibition of PTP1B delays erbB2-induced mammary tumorigenesis and protects from lung metastasis.Among the isolated compounds, erystgallin A along with isolated compounds was evaluated for their inhibitory effects on protein tyrosine phosphatase-1B (PTP1B), as well as their growth inhibition on MCF7.19836230

 






Copyright © 2012. Subhash M. Agagrwal. All Rights Reserved.